The stock of Sonnet BioTherapeutics Holdings Inc (SONN) has seen a 18.66% increase in the past week, with a 49.81% gain in the past month, and a -37.71% decrease in the past quarter. The volatility ratio for the week is 11.35%, and the volatility levels for the past 30 days are at 10.83% for SONN. The simple moving average for the past 20 days is 25.71% for SONN’s stock, with a -31.23% simple moving average for the past 200 days.
Is It Worth Investing in Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) Right Now?
Additionally, the 36-month beta value for SONN is 0.46. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SONN is 4.92M and currently, short sellers hold a 0.90% ratio of that float. The average trading volume of SONN on September 18, 2024 was 137.31K shares.
SONN) stock’s latest price update
Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) has experienced a rise in its stock price by 13.35 compared to its previous closing price of 0.87. However, the company has seen a gain of 18.66% in its stock price over the last five trading days. globenewswire.com reported 2024-09-04 that PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) — Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that it will participate in the Virtual Investor Closing Bell Series on Monday, September 9, 2024, at 4:00 PM ET.
SONN Trading at 22.70% from the 50-Day Moving Average
After a stumble in the market that brought SONN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.16% of loss for the given period.
Volatility was left at 10.83%, however, over the last 30 days, the volatility rate increased by 11.35%, as shares surge +46.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.44% upper at present.
During the last 5 trading sessions, SONN rose by +18.66%, which changed the moving average for the period of 200-days by -33.45% in comparison to the 20-day moving average, which settled at $0.7993. In addition, Sonnet BioTherapeutics Holdings Inc saw -43.39% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SONN
Current profitability levels for the company are sitting at:
- -219.69 for the present operating margin
- -0.45 for the gross margin
The net margin for Sonnet BioTherapeutics Holdings Inc stands at -142.9. The total capital return value is set at -4.57. Equity return is now at value -264.57, with -100.88 for asset returns.
Based on Sonnet BioTherapeutics Holdings Inc (SONN), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -66.56. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -180.67.
Currently, EBITDA for the company is -18.68 million with net debt to EBITDA at 0.28. When we switch over and look at the enterprise to sales, we see a ratio of 30.79. The receivables turnover for the company is 0.11for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.65.
Conclusion
In conclusion, Sonnet BioTherapeutics Holdings Inc (SONN) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
